Dear Ms. Neall:

Please refer to your supplemental new drug application dated October 01, 2009, received October 01, 2009, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Accolate (zafirlukast) tablets.

We also acknowledge receipt of your submission dated February 04, 2010.

This Prior Approval Labeling Supplemental new drug application provides for additional language regarding Churg-Strauss Syndrome in the PRECAUTIONS and ADVERSE REACTIONS sections of the prescribing information.

We have completed our review of this application, as amended. This application is approved, effective on the date of this letter, for use as recommended in the content of labeling [21 CFR 314.50(1)] in structured product labeling (SPL) format submitted on February 04, 2010.

As soon as possible, but no later than 14 days from the date of this letter, submit, using the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format, as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm, that is identical to the enclosed labeling (text for the package insert) and include the labeling changes proposed in any pending “Changes Being Effected” (CBE) supplements. Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including pending “Changes Being Effected” (CBE) supplements, for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format that includes the changes approved in this supplemental application.
NDA 20-547/S-029

If you issue a letter communicating important information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH  
Food and Drug Administration  
5515 Security Lane  
HFD-001, Suite 5100  
Rockville, MD 20852

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Sadaf Nabavian, Regulatory Project Manager, at (301) 796-2777.

Sincerely,

[See appended electronic signature page]

Badrul A. Chowdhury, M.D., Ph.D.  
Director  
Division of Pulmonary, Allergy, and Rheumatology Drug Products  
Office of Drug Evaluation II  
Center for Drug Evaluation and Research  
Enclosure: Approved Labeling

Enclosure: Approved Labeling
<table>
<thead>
<tr>
<th>Application Type/Number</th>
<th>Submission Type/Number</th>
<th>Submitter Name</th>
<th>Product Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDA-20547</td>
<td>SUPPL-29</td>
<td>ASTRAZENECA UK LTD</td>
<td>ACCOLATE (ZAFIRLUKAST) ORAL TABS 20MG</td>
</tr>
</tbody>
</table>

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/
LYDIA I GILBERT MCCLAIN
07/14/2010
Deputy Director